Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Do We have the Evidence to Repurpose Levamisole for Treatment of COVID 19?

Author(s): Keshab Mukhopadhyay, Chanchal Kumar Dalai, Ritesh Singh, Shah Newaz Ahmed* and Kushal Banerjee

Volume 16, Issue 2, 2021

Published on: 31 December, 2020

Page: [142 - 147] Pages: 6

DOI: 10.2174/1574885515999201231204530

Price: $65

Abstract

The human civilization is reeling under the COVID19 pandemic with no promising news of any effective treatment against the infection to date. A number of drugs have been repurposed without any remarkable efficacy. Amidst the crisis, utilising immunomodulators for boosting host immunity to mitigate disease severity and infectivity appears a viable option. In this article, we have explored the contemporary scientific evidence about levamisole for its potential use in COVID 19. Though the primary pharmacological use of the drug is as an anthelminthic, its immunostimulatory action has been shown to increase T-cell function, neutrophilic chemotaxis and immunoglobulin production both in vitro and in vivo. Clinically, the drug has been used with limited success in the treatment of herpes and HIV. The potential role of the drug in COVID 19 stems from the fact that the immunostimulant action can initiate a strong immune response and surmount the surreptitious virus, which evades host cell immunity. However, great caution has to be exercised in deciding the dosing schedule because the drug-disease interaction, especially the fatal hyperimmune response, is unknown and unpredictable. Being a widely available drug, enlisted in the WHO List of Essential Medicine, without any major safety issue, the drug is already in clinical trials carrying out worldwide. As the pandemic continues to ravage mankind with unabated intensity, any favourable outcome is eagerly awaited from the ongoing trials with levamisole and other drugs.

Keywords: Levamisole, COVID 19, immunomodulator, SARS CoV2, in vitro, in vivo.

« Previous Next »
Graphical Abstract

[1]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment Coronavirus (COVID-19). StatPearls. Treasure Island, FL: StatPearls Publishing 2020.
[2]
Lombardy Section Italian Society Infectious and Tropical Diseases. Vademecum for the treatment of people with COVID-19. Infez Med 2020; 28: 143-52.
[3]
Mulcahy G, Quinn PJ. A review of immunomodulators and their application in veterinary medicine. J Vet Pharmacol Ther 1986; 9(2): 119-39.
[http://dx.doi.org/10.1111/j.1365-2885.1986.tb00022.x] [PMID: 2425099]
[4]
Chandy ML, Soman C, Kumar SP, Kurup S, Jose R. Understanding molecular mechanisms in multivariant actions of levamisole as an anti-helminthic, anti-inflammatory, antioxidant, anti-neoplastic and immunomodulatory drug. J Oral Maxillofac Surg Med Pathol 2016; 28: 354-7.
[http://dx.doi.org/10.1016/j.ajoms.2016.03.004]
[5]
Merluzzi VJ, Badger AM, Kaiser CW, Cooperband SR. In vitro stimulation of murine lymphoid cell cultures by levamisole. Clin Exp Immunol 1975; 22(3): 486-92.
[PMID: 1083786]
[6]
Kimball ES, Clark MC, Schneider CR, Persico FJ. Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole. Clin Immunol Immunopathol 1991; 58(3): 385-98.
[http://dx.doi.org/10.1016/0090-1229(91)90129-X] [PMID: 2001605]
[7]
Holcombe RF, Milovanovic T, Stewart RM, Brodhag TM. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev 2001; 25(2): 183-91.
[PMID: 11341354]
[8]
Hersey P, Ho K, Werkmeister J, Abele U. Inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures of T and B cells by levamisole in vitro and in vivo. Clin Exp Immunol 1981; 46(2): 340-9.
[PMID: 6461457]
[9]
Anderson R, Glover A, Koornhof HJ, Rabson AR. In vitro stimulation of neutrophil motility by levamisole: maintenance of cgmp levels in chemotactically stimulated levamisole-treated neutrophils. J Immunol 1976; 117(2): 428-32.
[PMID: 181491]
[10]
Siwicki AK, Anderson DP, Dixon OW. In vitro immunostimulation of rainbow trout (Oncorhynchus mykiss) spleen cells with levamisole. Dev Comp Immunol 1990; 14(2): 231-7.
[http://dx.doi.org/10.1016/0145-305X(90)90094-U] [PMID: 1695158]
[11]
Witonsky S, Buechner-Maxwell V, Santonastasto A, et al. Can levamisole upregulate the equine cell-mediated macrophage (M1) dendritic cell (DC1) T-helper 1 (CD4 Th1) T-cytotoxic (CD8) immune response in vitro? J Vet Intern Med 2019; 33(2): 889-96.
[http://dx.doi.org/10.1111/jvim.15404] [PMID: 30693587]
[12]
Fu Y, Wang T, Xiu L, et al. Levamisole promotes murine bone marrow derived dendritic cell activation and drives Th1 immune response in vitro and in vivo. Int Immunopharmacol 2016; 31: 57-65.
[http://dx.doi.org/10.1016/j.intimp.2015.12.015] [PMID: 26706452]
[13]
Bourinbaiar AS, Lee-Huang S, Krasinski K, Borkowsky W. Anti-HIV effect of immunomodulating agent, levamisole, in vitro. Biomed Pharmacother 1994; 48(7): 327-30.
[http://dx.doi.org/10.1016/0753-3322(94)90179-1] [PMID: 7858164]
[14]
Rabson AR, Whiting DA, Anderson R, Glover A, Koornhof HJ. Depressed neutrophil motility in patients with recurrent herpes simplex virus infections: in vitro restoration with levamisole. J Infect Dis 1977; 135(1): 113-6.
[http://dx.doi.org/10.1093/infdis/135.1.113] [PMID: 833443]
[15]
Babiuk LA, Misra V. Levamisole and bovine immunity: in vitro and in vivo effects on immune responses to herpesvirus immunization. Can J Microbiol 1981; 27(12): 1312-9.
[http://dx.doi.org/10.1139/m81-201] [PMID: 6174193]
[16]
Urist MM, Boddie AW Jr, Townsend CM Jr, Holmes EC. In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy. J Thorac Cardiovasc Surg 1977; 73(2): 189-94.
[http://dx.doi.org/10.1016/S0022-5223(19)39943-X] [PMID: 834057]
[17]
Zamora S, Bhatti RA, Ablin RJ, Rao R, Baumgartner G, Guinan PD. In vitro stimulation of tumor-associated immunity in prostatic cancer by levamisole. Cell Mol Biol Incl Cyto Enzymol 1979; 25(1): 57-9.
[PMID: 574794]
[18]
Groveman DS, Borden EC. In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma. J Biol Response Mod 1983; 2(2): 167-74.
[PMID: 6644333]
[19]
Fidler IJ, Spitler LE. Effects of levamisole on in vivo and in vitro murine host response to syngeneic transplantable tumor. J Natl Cancer Inst 1975; 55(5): 1107-12.
[http://dx.doi.org/10.1093/jnci/55.5.1107] [PMID: 1206735]
[20]
Renoux M, Renoux G. Brucellosis, immunodepression, and levamisole. Lancet 1977; 1(8007): 372.
[http://dx.doi.org/10.1016/S0140-6736(77)91181-3] [PMID: 64900]
[21]
Van Wauwe J, Van Nijen G. Effect of levamisole on autologous rosette-forming cells in nude mice. Clin Exp Immunol 1977; 30(3): 465-8.
[PMID: 304789]
[22]
Fischer GW, Podgore JK, Bass JW, Kelley JL, Kobayaski GY. Enhanced host defense mechanisms with levamisole in suckling rats. J Infect Dis 1975; 132(5): 578-81.
[http://dx.doi.org/10.1093/infdis/132.5.578] [PMID: 171323]
[23]
Smolin G, Okumoto M, Friedlaender M. Treatment of herpes simplex keratitis with levamisole. Arch Ophthalmol Chic Ill 1978; 96: 1078-81.
[http://dx.doi.org/10.1001/archopht.1978.03910050598023]
[24]
Van der Maaten MJ, Schmerr MJ, Miller JM, Sacks JM. Levamisole does not affect the virological and serological responses of bovine leukemia virus-infected cattle and sheep. Can J Comp Med 1983; 47(4): 474-9.
[PMID: 6321003]
[25]
Strohmaier JE, Mohanty SB, Robl MG, Rockemann DD. Effect of a single therapeutic dose of levamisole on bovine viral diarrhea virus infection in calves. Microbiologica 1985; 8(4): 339-46.
[PMID: 3906367]
[26]
Kodama H, Mikami T, Izawa H. Effects of levamisole on pathogenesis of Marek’s disease. J Natl Cancer Inst 1980; 65(1): 155-9.
[PMID: 6248672]
[27]
Chen L-Y, Lin Y-L, Chiang B-L. Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 2008; 151(1): 174-81.
[http://dx.doi.org/10.1111/j.1365-2249.2007.03541.x] [PMID: 18005262]
[28]
Yin J, Jin H, Kang Y, et al. Efficacy of modified levamisole adjuvant on inactivated virus vaccine. Viral Immunol 2006; 19(3): 525-35.
[http://dx.doi.org/10.1089/vim.2006.19.525] [PMID: 16987070]
[29]
Yin J, Jin H, Yang F, et al. Synergistic effects of adjuvants interferon-gamma and levamisole on DNA vaccination against infection with Newcastle disease virus. Viral Immunol 2007; 20(2): 288-99.
[http://dx.doi.org/10.1089/vim.2006.0108] [PMID: 17603845]
[30]
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1-9.
[PMID: 32105090]
[31]
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75(7): 1564-81.
[32]
Boura P, Raptopoulou-Gigi M, Acriviadis E, Goulis G. Reevaluation of the effect of levamisole in chronic brucellosis: in vitro and in vivo effect on monocyte phagocytosis. J Immunopharmacol 1984; 6(3): 135-46.
[http://dx.doi.org/10.3109/08923978409019456] [PMID: 6333466]
[33]
O’Reilly RJ, Chibbaro A, Wilmot R, Lopez C. Correlation of clinical and virus-specific immune responses following levamisole therapy of recurrent herpes progenitalis. Ann N Y Acad Sci 1977; 284: 161-70.
[http://dx.doi.org/10.1111/j.1749-6632.1977.tb21947.x] [PMID: 212971]
[34]
Gupta M. Levamisole: A multi-faceted drug in dermatology. Indian J Dermatol Venereol Leprol 2016; 82(2): 230-6.
[http://dx.doi.org/10.4103/0378-6323.175927] [PMID: 26924410]
[35]
RECOVERY Collaborative Group. Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2021; 384(8): 693-704.
[36]
Available from: https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/ (Accessed on April 21, 2021).
[37]
O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 2020; 20(6): 335-7.
[http://dx.doi.org/10.1038/s41577-020-0337-y] [PMID: 32393823]
[38]
Goihman-Yahr M. Proposed use of thalidomide for the cytokine storm of COVID-19. Clin Dermatol 2020; 38(4): 508.
[http://dx.doi.org/10.1016/j.clindermatol.2020.04.015] [PMID: 32972614]
[39]
Khalil A, Kamar A, Nemer G. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? Front Immunol 2020; 11: 1248.
[http://dx.doi.org/10.3389/fimmu.2020.01248] [PMID: 32574274]
[40]
Uyaroğlu OA, Güven GS, Güllü İ. Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea? J Infect Dev Ctries 2020; 14(8): 844-6.
[http://dx.doi.org/10.3855/jidc.13101] [PMID: 32903227]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy